Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 15, 2016
Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factorsYasushi Honda, Masato Yoneda, Takaomi Kessoku, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Gastroesophageal varices evaluation using spleen-dedicated stiffness measurement by vibration-controlled transient elastographyKoki Nagai, Yuji Ogawa, Takashi Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 12, 2019
Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver diseaseAsako Nogami, Masato Yoneda, Takashi Kobayashi, et al.
BMJ Open|September 10, 2020
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver diseaseTakaomi Kessoku, Takashi Kobayashi, Anna Ozaki, et al.
Journal of Gastroenterology and Hepatology|June 1, 2018
New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zonesKento Imajo, Wataru Tomeno, Mineo Kanezaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 21, 2017
Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencingKikuko Hotta, Masataka Kikuchi, Takuya Kitamoto, et al.
Contemporary Clinical Trials Communications|January 21, 2020
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)Anna Ozaki, Masato Yoneda, Takaomi Kessoku, et al.
BMJ Open Diabetes Research & Care|February 17, 2021
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trialMasato Yoneda, Yasushi Honda, Yuji Ogawa, et al.
Plos One|June 14, 2013
Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitisYuji Ogawa, Kento Imajo, Masato Yoneda, et al.
Scientific Reports|October 28, 2022
A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costsTakashi Kobayashi, Yuji Ogawa, Satoru Shinoda, et al.
Pageof 12